Charles Allan Presents MY01 at LSI Europe '23

MY01 has developed a device to continuously monitor and manage acute compartment syndrome in muscles.
Charles Allan
Charles Allan



Charles Allan  0:00  
I'm very excited to present to you my our platform technology for managing extremity injuries. My name is Charlie Allan. The company's called MY01. MYO is muscle and 01 means digital. So the idea is that we're digitizing the muscle and their physicians are using this technology to make the right decision under pressure. We're a commercial stage, we've been out and done over 1000 patients. So far and top centers across the US and Canada, and Europe, we've got over 50 trauma centers that are using our technology today, onboarding two to five hospitals per month. So it's really we're really in this rapid growth. And I'm excited to tell you more about this platform. Over 18 million injury related admissions are going to be triaged in the ER today. All those are done with physical exam, and physical exams can't detect underlying pressure that's that's being developed. Of those 1.5 million will end up developing some sort of pressure related injury. And because of the delays in diagnosis, lead to significant limb and life threatening complications, costing billions of dollars to the healthcare system. This process today, because physical exams take are reliant on pain as the primary diagnosis, it takes a while and subjective data, it takes a very long time for the physicians to get a good idea of what's happening to this patient. And because of that time period, or the longer you wait, the worse the outcomes are going to be for that patient causing significant long term issues, which which can mean significant wound complications, all of which will add cost to the patient. And then jumping early. So over diagnosing also has its own underlying costs. What you can see here is a picture of what the underlying therapy is for these cases. So what you need to do is open up the muscle and relieve the pressure, obviously very invasive, and not something you'd want to do for no reason. So what if there was a platform to detect this pre symptomatically? And that's, that's really the question that we had, that the orthopod that developed this technology, Dr. Ed Harvey, came to our lab to help with finding a solution. And ultimately, time is tissue. Sensing early will save tissue. And that's what our technology has been able to show. Here's a real life case of a patient, where our technology was able to detect the underlying disease developing over time pre symptomatically, which gives the doctors an early warning sign of what's to come. So they can align their plan accordingly and make sure that they intervene at the right time, saving significant costs and avoiding significant complications. Now, we aren't just doing kids case studies, we've done large multicenter studies that have all completed enrollment. What you see here is some of the data that's come out of that that's over 150 patients across two prospective studies, we've what we've shown is five hours faster diagnosis for the technology, as well as 100% accuracy in diagnosis. So the product is helping doctors find the problem faster and more accurately, which ultimately lowers the care burden required to manage these patients and save significant costs to the hospital system. We've got a lot of IP around the sensing technology and the way we deploy the device, and the so about 10 patents. So far, we've got five more in process. And what we've been able to do is is make the technology is super easy to use. But there's a lot of complexity that's built into it. So this physician doesn't need to know everything that's happening. And all they have is a very reliable data source that they can use to make better clinical judgment. And then it all relates to mobile app, which allows for an ability to view the data from a distance, which can also help with care team collaboration, another area where there's opportunity that we've we've been able to help because care team collaboration is a key part of making sure that the patients get the best the best possible outcome. This is a growing body of evidence. We've got a large clinical studies that have happened and we have others that are ongoing. Some of these are actually funded by the Department of Defense. You can see some very important hospitals that are part of that. So John Hopkins, Carolinas Medical Center at Vanderbilt Hennepin and what's great is that now the new studies that are going on, they've already decided that our product is the gold standard and they're using that to test new therapies. To avoid those large open wounds that we saw earlier in the presentation, so it's exciting to see where this technology is going and how it's advancing care for these patients with extremity trauma. As I said earlier, we launched in q4 of 2022. And we've been clearly gaining significant traction in the market, where you can see is that we're onboarding significant number of hospitals and each hospital that we've on boarded, has started to reorder the product. We've got a strong pipeline moving forward, and we see that growth happening and continuing to happen over the next several years. And and we're excited about the pathway that that we're going on, our strategy has been focused on IDN. So integrated delivery networks, and that process is starting to really accelerate. I said that earlier, but over 120 days, it takes for us about to get a new hospital onboarding. I was talking about extremity trauma. That's really where we focused at the beginning. But we've a platform technology. And we've already got commercial traction, and usage in vascular as well as sports medicine applications. So we're really excited about where and how this this product is evolving and how it's really helping change the standard of care, and how we manage patients in multiple different facets of of medicine, we've got a clear pathway of how to bring this product from the pilot launch the full launch and then to the standard of care. And, and we're excited about the the next steps that are happening for this platform. We've raised 12.6 $18.5 million to date. We closed the funding round in March of this year. And we're out raising another 7.5 million to extend our runway. But the goal really is focused on getting more clinical data. So we're going to be running a registry, where we're going to focus on taking the data and clinical commercial activity that we're seeing now and converting that into more clinical data that will help us with private payer reimbursement, as well as showing the expansion of how this product can be used. We've got several use cases that are evolving, not just from the preoperative side, technology is also used intraoperatively to improve how we treat these patients. And then postoperatively we're able to actually help with managing the patients and getting that out of the hospital faster. Which all of that helps drive down costs also improves how, how the economics of these types of cases. So we're really excited about our pathway moving forward and how this platform has been built out. Just to summarize, we also have a really good team. He has got a significant track record day in the cardiology space, the vascular space, as well as the orthopedic world. And then Geno's leading our sales team in the US. To summarize, sensing early saves tissue, we've got a significant number of devices used to date we're in market and a large market opportunity. And we're looking for partners to help us with on our journey. So thank you very much

LSI Europe ‘24 is filling fast. Secure your spot today to join Medtech and Healthtech leaders.

September 16-20, 2024 The Ritz-Carlton - Sintra, Portugal Register arrow